Showing 1 – 3 of 3
Relevance | Newest | Oldest |
  • Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial

    Abstract Full Text
    is active quiz has multimedia
    JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011

    This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.

  • Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes

    Abstract Full Text
    open access
    ÁñÁ«ÊÓƵ Netw Open. 2022; 5(8):e2225600. 10.1001/jamanetworkopen.2022.25600

    This cohort study evaluates the association between gonadotropin-releasing hormone agonist use, prostate cancer diagnosis, and cardiovascular (CVD) risk in men with type 2 diabetes.

  • Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results

    Abstract Full Text
    open access
    ÁñÁ«ÊÓƵ Netw Open. 2019; 2(11):e1914689. 10.1001/jamanetworkopen.2019.14689

    This cohort study examines the association between antidiabetic medication and prostate-specific antigen (PSA) levels, frequency of PSA testing and biopsy, and detection of prostate cancer at biopsy among Swedish men with diabetes.